SynOx Therapeutics, a prominent biopharmaceutical company based in Dublin, Ireland, and Oxford, UK, is forging ahead with its mission to develop innovative treatments for disorders linked to CSF-1 and macrophage activity. Recently, the company announced the successful completion of an extension to its Series B funding round, which has now raised a remarkable total of $92 million. The funding round was spearheaded by Gilde Healthcare, a well-respected investment firm, and saw participation from notable investors such as Forbion, HealthCap, and Bioqube Ventures. This significant influx of capital is expected to propel SynOx into the next phases of its clinical development, particularly with its promising drug candidate, emactuzumab, which targets crucial pathways involved in these complex disorders.
Under the leadership of CEO Ray Barlow, SynOx is diligently working to advance emactuzumab, a monoclonal antibody designed to inhibit the CSF-1 receptor (CSF-1R).
This drug is aimed at treating Tenosynovial Giant Cell Tumour (TGCT) and several other conditions influenced by CSF-1 and macrophage activity. Following the successful closing of the Series B extension, SynOx has announced an important milestone: the first patients have been dosed in its Phase 3 registrational study of emactuzumab. This pivotal study, named TANGENT, is structured as a global, multi-center, randomized, double-blind, placebo-controlled trial, a rigorous approach that will provide reliable data regarding the drug's safety and efficacy among patients diagnosed with TGCT.
The primary objective of the TANGENT trial is to evaluate the overall response rate (ORR) of emactuzumab, offering investigators a clear measure of the drug's impact. Furthermore, the study will include a variety of secondary outcomes, such as assessments of functional health and quality of life, changes in tumor volume, and the duration of the drug's effectiveness. With plans to enroll approximately 130 patients, SynOx is poised to gather substantial evidence that could potentially revolutionize the therapeutic landscape for TGCT and other related conditions. As the company moves forward, the expertise of Arthur Franken from Gilde Healthcare, who will join the SynOx Board of Directors, will be invaluable in navigating this critical phase of development.
Click here for a full list of 6,481+ startup investors in the UK